JOINN Biologics Inc. receives US $60 Million Series A financing led by HG Capital, the fund is dedicated to help JOINN Biologics build a comprehensive biopharmaceutical service platform and become a global biologics CDMO leader.

JOINN Biologics Inc. (hereinafter referred to as “JOINN Bio”) recently completed a $60 million Series A financing. The financing was led by HG Capital, and Nestbio Capital, Hong Kong LINKAGE Holdings, Xiangtang Capital and other institutions jointly participated in the investment. This round of financing will be mainly used for the construction of 100,000-liter capacity for biopharmaceutical manufacturing of JOINN Bio, as well as business expansion in China and the United States.